Technical Trend Shift and Price Movement
The stock closed at ₹8,173.90 on 5 Aug 2026, down 1.47% from the previous close of ₹8,296.00. This decline comes despite a daily high of ₹8,295.20 and a low of ₹8,161.95, indicating intraday volatility but an overall downward bias. Astrazeneca Pharma India Ltd’s 52-week price range spans from ₹7,630.00 to ₹9,850.00, with the current price sitting closer to the lower end, underscoring recent weakness.
The technical trend has deteriorated from mildly bearish to outright bearish, signalling increased selling pressure. This shift is corroborated by the daily moving averages, which remain bearish, suggesting that short-term momentum is unfavourable. The stock’s inability to sustain levels above key moving averages points to a lack of buying conviction among investors.
MACD and Momentum Indicators
The Moving Average Convergence Divergence (MACD) indicator presents a mixed but predominantly negative picture. On a weekly basis, the MACD is bearish, reflecting downward momentum over the medium term. The monthly MACD is mildly bearish, indicating that while the longer-term trend is not strongly negative, it is far from positive. This divergence between weekly and monthly MACD readings suggests that the stock may be in a transitional phase but with a bias towards further weakness.
The KST (Know Sure Thing) indicator aligns with this view, showing bearish signals on the weekly chart and mildly bearish on the monthly chart. These momentum oscillators confirm that the stock’s price action is losing strength and may continue to face downward pressure in the near term.
RSI and Bollinger Bands Analysis
The Relative Strength Index (RSI) on both weekly and monthly timeframes currently shows no clear signal, hovering in neutral territory. This lack of a definitive RSI signal suggests that the stock is neither oversold nor overbought, but the absence of bullish momentum is a concern given the other bearish indicators.
Bollinger Bands on weekly and monthly charts are mildly bearish, indicating that price volatility is skewed towards the downside. The stock price is likely testing the lower band, which often acts as a support level; however, the mild bearishness implies that this support may be fragile and susceptible to breakdown if selling intensifies.
Volume and Dow Theory Signals
On-Balance Volume (OBV) readings provide a slightly more optimistic perspective, with mildly bullish signals on both weekly and monthly charts. This suggests that despite price declines, there is some accumulation occurring, possibly from long-term investors viewing current levels as attractive. However, this volume support has not yet translated into a sustained price recovery.
Dow Theory assessments are mixed, with weekly signals mildly bullish but monthly signals mildly bearish. This divergence highlights the uncertainty in the stock’s trend direction, with short-term technicals showing some resilience while longer-term momentum remains under pressure.
Crushing the market! This Small Cap from Aerospace & Defense just earned its spot in our Top 1% with impressive gains. Don't let this opportunity slip through your hands.
- - Recent Top 1% qualifier
- - Impressive market performance
- - Sector leader
Comparative Performance and Market Context
When analysing Astrazeneca Pharma India Ltd’s returns relative to the broader market, the stock has underperformed the Sensex over most recent periods. Over the past week, the stock gained 1.29%, lagging behind the Sensex’s 2.17% rise. Over one month, the stock declined by 1.49%, while the Sensex rose 0.86%. Year-to-date, Astrazeneca Pharma India Ltd has fallen 9.28%, compared to the Sensex’s 7.97% decline.
Over longer horizons, however, the stock has delivered exceptional returns. Over three years, it has surged 115.22%, vastly outperforming the Sensex’s 19.34%. The five-year return of 137.60% also dwarfs the Sensex’s 44.25%, and the ten-year return of 696.91% is particularly impressive against the Sensex’s 182.99%. This long-term outperformance highlights the company’s strong growth trajectory despite recent technical setbacks.
Mojo Score and Rating Revision
MarketsMOJO’s latest assessment assigns Astrazeneca Pharma India Ltd a Mojo Score of 37.0, categorising it as a Sell. This represents a downgrade from the previous Hold rating as of 2 Jan 2026. The downgrade reflects the deteriorating technical indicators and the bearish momentum that has emerged in recent months. The company is classified as a small-cap within the Pharmaceuticals & Biotechnology sector, which often entails higher volatility and sensitivity to market shifts.
Investors should note that the downgrade is driven primarily by technical factors rather than fundamental changes. The stock’s valuation and sector dynamics remain important considerations, but the current technical environment suggests caution for short- to medium-term trading.
Outlook and Investor Considerations
The prevailing bearish technical signals, including the daily moving averages, weekly MACD, and KST indicators, suggest that Astrazeneca Pharma India Ltd may face continued downward pressure in the near term. The neutral RSI and mildly bearish Bollinger Bands indicate limited upside momentum, while the mildly bullish OBV hints at some underlying support from volume.
Given the mixed signals from Dow Theory and volume indicators, investors should monitor key support levels closely, particularly around the ₹7,630 52-week low. A sustained break below this level could trigger further declines. Conversely, a rebound above the daily moving averages and a shift in MACD to bullish territory would be required to signal a reversal in momentum.
In the context of the broader Pharmaceuticals & Biotechnology sector, Astrazeneca Pharma India Ltd’s small-cap status means it is more susceptible to market swings and sector-specific risks. Investors seeking exposure to this sector may wish to consider alternative stocks with stronger technical profiles and higher Mojo Grades.
Why settle for Astrazeneca Pharma India Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology small-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Summary
Astrazeneca Pharma India Ltd’s technical parameters have shifted decisively towards a bearish stance, with multiple indicators signalling weakening momentum. The downgrade to a Sell rating by MarketsMOJO reflects this technical deterioration amid a challenging market backdrop. While the stock’s long-term returns remain impressive, near-term risks are elevated, and investors should exercise caution.
Monitoring key technical levels and volume trends will be critical in assessing whether the stock can stabilise or if further declines are imminent. For those seeking exposure to the Pharmaceuticals & Biotechnology sector, alternative small-caps with stronger technicals may offer more attractive risk-reward profiles at present.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
